{"id":16577,"date":"2016-03-06T13:22:42","date_gmt":"2016-03-06T20:22:42","guid":{"rendered":"https:\/\/www.accessrx.com\/blog\/?p=16577"},"modified":"2018-11-28T21:27:16","modified_gmt":"2018-11-28T21:27:16","slug":"viagra-competitor-could-be-on-the-way-from-israeli-pharma-firm","status":"publish","type":"post","link":"https:\/\/www.edrugstore.com\/blog\/erectile-dysfunction\/viagra\/viagra-competitor-could-be-on-the-way-from-israeli-pharma-firm\/","title":{"rendered":"New ED Drug Could Be on the Way from Israeli Pharma Firm"},"content":{"rendered":"

I<\/span>srael’s Can-Fite BioPharm Ltd. has developed a promising new treatment for erectile dysfunction. Code-named CF602, the drug is expected to begin Phase I clinical trials soon.<\/em><\/strong><\/p>\n

Viagra and other erectile dysfunction medications may soon have some added competition as an Israeli-based pharmaceutical company enters the final stages of patenting a new medication for the treatment of the condition. This next-generation medication was discovered during research on diabetic rats and may prove to be a key treatment for men who suffer from both diabetes and erectile dysfunction.<\/p>\n

The prospective Israeli ED drug, code-named CF602, is being developed and tested by Can-Fite BioPharma Ltd., which is headquartered in Petah Tikva, an eastern suburb of Tel Aviv. In July 2018, Can-Fite was granted Australian and Chinese patents on the drug, which has shown promise as an ED treatment in preclinical testing.<\/p>\n

The company also reported in late 2018 that it was putting the finishing touches on an investigational new drug, or IND, application for submission to the U.S. Food and Drug Administration. The Israeli company also noted that it hopes soon to launch Phase I clinical trials on the drug.<\/p>\n

Erectile dysfunction affects a large percentage of the male population who are over the age of 50, but more and more men under 50 are falling victim to it as well, for both physical and psychological reasons. As the health of our male population decreases due to aging and poor lifestyle choices, the need for effective medications to treat conditions such as erectile dysfunction that work well with treatments for chronic diseases such as diabetes and cardiovascular disease becomes even more important.<\/p>\n

Pharmaceutical Impact of ED<\/h3>\n
\"\"<\/a>
Finding new and better ways to treat ED is a major focus of pharmaceutical research.<\/em><\/figcaption><\/figure>\n

Erectile dysfunction treatment has become a major focus for pharmaceutical companies. With a projected $7.1 billion market by 2024, the development of new drugs to join those already on the market is a significant goal for drug companies’ research and development departments.<\/p>\n

Erectile dysfunction, the inability to develop or maintain an erection suitable for intercourse, can be caused by a variety of external influences and internal conditions and diseases. It is often the result of poor lifestyle choices, including smoking, drug abuse, and overindulgence in alcohol. Many diseases can affect the body’s ability to get and keep an erection, among them diabetes.<\/p>\n

The circulatory system and neurological system both play a pivotal role in the complicated process that results in an erection, so any reduction in blood flow or nerve function can have a serious impact. Diabetes, in particular the aggressive effects of diabetes mellitus, damages nerve function and impairs the blood supply throughout the body. Though no concrete causal relationship as been established between diabetes and erectile dysfunction, doctors have found that men who have diabetes face an increased risk of developing ED.<\/p>\n

An aging population and rampant obesity have led to a sharp increase in the development of diabetes mellitus cases, with younger men falling victim to what was once an “old man’s” disease. With type 2 diabetics becoming more and more common at even younger ages, the need for a reliable erectile dysfunction medication that is safe to use for someone with this condition has become an even greater priority for pharmaceutical companies that want to be a part of this booming industry.<\/p>\n

Discovering New Treatments<\/h3>\n

Pharmaceutical companies spend thousands of hours on research, analyzing each prospective medication or compound to discover its latent qualities and what types of diseases or conditions it may affect. Many medications that have a particular function have been found to affect the body in a host of other positive ways, allowing the company to market the new medication for the treatment of several different illnesses.<\/p>\n

Erectile dysfunction treatments are often found as a side effect of a drug’s testing for the treatment of other conditions and illnesses, especially those geared toward the treatment of cardiovascular disease. For example, sildenafil citrate, the active ingredient in Viagra, was originally researched as a potential new treatment for angina and intractable high blood pressure. While it failed to perform as well as hoped in treating those ailments, men who participated in clinical trials for the drug reported an interesting side effect. They suddenly found it easier to get and keep an erection, and this effect was also observed in a number of men who had previously been diagnosed with ED. This serendipitous discovery sent Pfizer research scientists on a new path with respect to the drug, and the end-result was Viagra.<\/p>\n

Israel’s Role in Pharmaceuticals<\/h3>\n
\"\"<\/a>
Petah Tikva is a major Israeli industrial center, second in size only to Haifa.<\/em><\/figcaption><\/figure>\n

Israel has been leading the way in the pharmaceutical industry since its founding in 1948. Among the many German migrants who entered the country following the Second World War were a large number of scientists and researchers. This surge of intellectual capital allowed the new nation to carve out a niche for itself in a number of industries with a focus on research, including pharmaceutical manufacturing.<\/p>\n

Since the 1970s, the life sciences industry in Israel has steadily grown with a great surge occurring over the last decade. The country’s universities turn out thousands of graduates every year, many of whom go directly into entry-level positions at pharmaceutical research and development firms in the country. In addition to the home-grown companies Teva Pharmaceuticals Industries and Anchiano Therapeutics, many foreign drug companies have established R&D facilities in Israel as well, including Merck and Johnson & Johnson.<\/p>\n

Generic drugs are a major part of the pharmaceutical industry in Israel, with firms such as Teva accounting for nearly 80 percent of the generic drugs sold in Europe and North America. In addition, the development of new medication is a priority. For example, Teva has developed a treatment for multiple sclerosis called Copaxone.<\/p>\n

Developing new medications that treat a variety of illnesses is also a priority for firms such as Can-Fite.<\/a>\u00a0The company developmental focus is primarily on new pharmaceutical treatments for cancer and a host of autoimmune diseases. Its CF101 drug has been used for a variety of illnesses and conditions, including psoriasis, rheumatoid arthritis, and glaucoma, among others. CF102, another medication Can-Fite has developed, is used for the treatment of a number of liver diseases.<\/p>\n

Can-Fite recently entered the final stages of the U.S. patenting process for their “A3 Adenosine Receptor Allosteric Modulators.” The patent will cover not only the preparation of pharmaceuticals based on this modulator therapy but also the use of these pharmaceuticals across all therapeutic indications, meaning the medications produced can be used for a variety of illnesses. CF602, a prospective treatment for ED, is one of several applications to emerge from this research.<\/p>\n

Adenosine and ED<\/h3>\n

Adenosine plays an important role in the body’s functions. A neuromodulator, adenosine functions by slowing down and suppressing synaptic transmissions. Adenosine has been synthesized into a variety of medications to treat conditions that require body functions to be slowed, such as supraventricular tachycardia, in which the heart is beating too fast.<\/p>\n

The majority of the research that Can-Fite is focusing on involves the effects of A3 adenosine receptors (A3AR) and their use to treat a wide variety of conditions and diseases. CF602 was originally being developed as a treatment for inflammation, including a variety of autoimmune inflammatory conditions. While researching the effects of CF602 on rats with diabetes, the medication demonstrated an effect similar to that of sildenafil citrate, a generic drug used to treat erectile dysfunction and is also marketed under the brand name Viagra. According to Can-Fite, this new drug appears to be superior to sildenafil in the treatment of erectile dysfunction, and since three out of four men with diabetes also suffer from erectile dysfunction, the new drug will be marketed primarily to this group.<\/p>\n

Conclusion<\/h3>\n

The development of new medications is an ongoing process, with pharmaceutical companies in Israel and around the world discovering new compounds and substances every day. With each new discovery comes the opportunity to use those drugs for multiple illnesses and finding ways to treat non-life-threatening conditions such as erectile dysfunction. As health issues increase for men, coping with issues like erectile dysfunction become more important to preserving one’s health and well-being. As Israel prepares to debut its new erectile dysfunction treatment, it can only serve to improve the future quality and variety of treatments that will become available.<\/p>\n

While Can-Fite’s prospective new entry into the ED medications market wends its way toward approval, a wide array of other drugs are already available to men who are having difficulty getting and keeping an erection. Longtime online facilitator eDrugstore.com offers the full range of ED medications, including both brand-name and generic products, all of which can be ordered online. Headquartered in Tempe, Arizona, eDrugstore has been in business since the late 1990s. To learn more, visit its Erectile Dysfunction page<\/a>.<\/p>\n

Author Bio:<\/i><\/p>\n

Gabriella Messina<\/a> is an author who has written online content on a variety of health and wellness topics, including fitness and nutrition, diet supplementation, prescription drugs and a variety of diseases and conditions.<\/i>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Israel’s Can-Fite BioPharm Ltd. has developed a promising new treatment for erectile dysfunction. Code-named CF602, the drug is expected to begin Phase I clinical trials soon. Viagra and other erectile dysfunction medications may soon have some added competition as an Israeli-based pharmaceutical company enters the final stages of patenting a new medication for the treatment […]<\/p>\n","protected":false},"author":1,"featured_media":24653,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_autoblog_aioseo_focus_keyphrase":"","_autoblog_aioseo_title":"","_autoblog_aioseo_description":"","footnotes":""},"categories":[17],"tags":[23],"class_list":["post-16577","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-viagra","tag-erectile-dysfunction-2"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t